loading
전일 마감가:
$137.00
열려 있는:
$137.87
하루 거래량:
96,272
Relative Volume:
0.11
시가총액:
$13.75B
수익:
$2.41B
순이익/손실:
$305.80M
주가수익비율:
47.02
EPS:
2.95
순현금흐름:
$492.20M
1주 성능:
+1.04%
1개월 성능:
-3.73%
6개월 성능:
+58.13%
1년 성능:
+23.97%
1일 변동 폭
Value
$136.10
$138.88
1주일 범위
Value
$135.59
$141.14
52주 변동 폭
Value
$84.23
$154.61

뉴로크린 바이오사이언시스 Stock (NBIX) Company Profile

Name
명칭
Neurocrine Biosciences Inc
Name
전화
(858) 617-7600
Name
주소
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Name
직원
1,800
Name
트위터
Name
다음 수익 날짜
2024-10-30
Name
최신 SEC 제출 서류
Name
NBIX's Discussions on Twitter

NBIX을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Drug Manufacturers - Specialty & Generic icon
NBIX
Neurocrine Biosciences Inc
138.65 13.59B 2.41B 305.80M 492.20M 2.95
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
144.66 63.27B 9.39B 2.62B 2.22B 5.8121
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
14.36 45.67B 29.96B 957.25M 4.77B 0.2956
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
9.095 39.27B 14.26B 1.98B 2.47B 0.4327
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
20.30 23.02B 16.70B -157.13M 1.19B -0.1446
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
446.01 20.66B 3.08B 1.24B 1.07B 25.61

뉴로크린 바이오사이언시스 Stock (NBIX) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-07-21 개시 Truist Buy
2025-07-10 개시 Goldman Buy
2025-04-15 업그레이드 Needham Hold → Buy
2025-04-14 업그레이드 RBC Capital Mkts Sector Perform → Outperform
2025-02-11 개시 Deutsche Bank Hold
2024-10-10 재개 Raymond James Outperform
2024-08-29 업그레이드 Piper Sandler Neutral → Overweight
2024-04-24 업그레이드 Wells Fargo Equal Weight → Overweight
2023-12-13 재개 Citigroup Neutral
2023-12-12 개시 Deutsche Bank Buy
2023-10-24 재개 Cantor Fitzgerald Overweight
2023-08-21 재확인 Mizuho Neutral
2023-07-24 업그레이드 SVB Securities Market Perform → Outperform
2023-07-06 업그레이드 BMO Capital Markets Underperform → Market Perform
2023-05-04 업그레이드 Guggenheim Neutral → Buy
2023-03-30 업그레이드 Canaccord Genuity Hold → Buy
2023-03-03 업그레이드 Evercore ISI In-line → Outperform
2023-02-03 업그레이드 Morgan Stanley Equal-Weight → Overweight
2022-11-14 다운그레이드 Evercore ISI Outperform → In-line
2022-10-11 개시 UBS Buy
2022-09-26 개시 Wells Fargo Equal Weight
2022-06-06 재개 Jefferies Buy
2022-03-03 다운그레이드 Piper Sandler Overweight → Neutral
2022-02-25 업그레이드 Goldman Neutral → Buy
2022-01-18 다운그레이드 RBC Capital Mkts Outperform → Sector Perform
2021-11-19 개시 BMO Capital Markets Underperform
2021-11-17 업그레이드 JP Morgan Neutral → Overweight
2021-10-14 다운그레이드 Morgan Stanley Overweight → Equal-Weight
2021-09-23 재개 Needham Hold
2021-08-06 다운그레이드 Canaccord Genuity Buy → Hold
2021-05-18 재개 Goldman Neutral
2021-05-06 업그레이드 Barclays Equal Weight → Overweight
2021-02-02 개시 Raymond James Outperform
2020-09-30 개시 The Benchmark Company Hold
2020-08-04 다운그레이드 JP Morgan Overweight → Neutral
2020-06-29 다운그레이드 Goldman Buy → Neutral
2020-06-09 개시 Wedbush Outperform
2020-03-06 개시 Citigroup Buy
2020-02-27 개시 Barclays Equal Weight
2020-02-24 개시 William Blair Outperform
2020-02-06 개시 Mizuho Neutral
2020-02-05 재확인 H.C. Wainwright Buy
2019-12-13 다운그레이드 Credit Suisse Outperform → Neutral
2019-08-07 개시 RBC Capital Mkts Outperform
2019-07-16 개시 Oppenheimer Outperform
2019-06-05 개시 Guggenheim Neutral
2019-05-21 개시 Credit Suisse Outperform
2019-04-22 업그레이드 JP Morgan Neutral → Overweight
2019-04-12 개시 Evercore ISI Outperform
2019-02-06 재확인 BofA/Merrill Buy
2019-01-23 다운그레이드 JP Morgan Overweight → Neutral
2018-12-13 개시 Goldman Buy
2018-11-21 개시 Canaccord Genuity Buy
모두보기

뉴로크린 바이오사이언시스 주식(NBIX)의 최신 뉴스

pulisher
Oct 07, 2025

Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2025 Financial Results - The AI Journal

Oct 07, 2025
pulisher
Oct 07, 2025

Q3 2025 Results: Neurocrine Biosciences to Host Oct. 28 Webcast & Call at 1:30 p.m. PT; Replay 1 Month - Stock Titan

Oct 07, 2025
pulisher
Oct 07, 2025

How New Three-Year INGREZZA Data at Neurocrine Biosciences (NBIX) Has Changed Its Investment Story - simplywall.st

Oct 07, 2025
pulisher
Oct 07, 2025

A Fresh Look at Neurocrine Biosciences (NBIX) Valuation After Latest INGREZZA Clinical Study Results - Yahoo Finance

Oct 07, 2025
pulisher
Oct 06, 2025

Earnings call transcript: Neurocrine Q2 2025 shows strong sales growth By Investing.com - Investing.com Australia

Oct 06, 2025
pulisher
Oct 06, 2025

Neurocrine Biosciences names Mike Sibley to lead neuropsychiatry franchise By Investing.com - Investing.com Nigeria

Oct 06, 2025
pulisher
Oct 06, 2025

Neurocrine reports sustained benefits of INGREZZA for Huntington’s chorea By Investing.com - Investing.com Nigeria

Oct 06, 2025
pulisher
Oct 06, 2025

20+ years commercial leader Mike Sibley named Neurocrine SVP & GM, Neuropsychiatry to lead INGREZZA franchise - Stock Titan

Oct 06, 2025
pulisher
Oct 06, 2025

Earnings call transcript: Neurocrine Q2 2025 shows strong sales growth - Investing.com India

Oct 06, 2025
pulisher
Oct 06, 2025

Is Neurocrine Biosciences Inc. a candidate for recovery playJuly 2025 Update & Low Drawdown Trading Techniques - newser.com

Oct 06, 2025
pulisher
Oct 06, 2025

What MACD signals say about Neurocrine Biosciences Inc.Insider Selling & Smart Allocation Stock Tips - newser.com

Oct 06, 2025
pulisher
Oct 06, 2025

Intraday pattern recognizer results for Neurocrine Biosciences Inc.2025 Market Overview & Daily Price Action Insights - newser.com

Oct 06, 2025
pulisher
Oct 06, 2025

Neurocrine reports sustained benefits of INGREZZA for Huntington’s chorea - Investing.com

Oct 06, 2025
pulisher
Oct 06, 2025

Neurocrine shows 3-year safety data for Huntington's drug INGREZZA - StreetInsider

Oct 06, 2025
pulisher
Oct 06, 2025

Neurocrine Biosciences Presents New Three-Year Data Demonstrating Sustained Clinical Benefits and Established Safety Profile of INGREZZA® (valbenazine) Capsules for Huntington's Disease Chorea - PR Newswire

Oct 06, 2025
pulisher
Oct 06, 2025

Technical signs of recovery in Neurocrine Biosciences Inc.Weekly Market Report & Risk Controlled Daily Trade Plans - newser.com

Oct 06, 2025
pulisher
Oct 06, 2025

Will Neurocrine Biosciences Inc. stock deliver consistent dividends2025 Year in Review & Daily Stock Trend Reports - newser.com

Oct 06, 2025
pulisher
Oct 05, 2025

What the G7 Rare Earths News Means for Neurocrine Biosciences Valuation in 2025 - simplywall.st

Oct 05, 2025
pulisher
Oct 05, 2025

Will Neurocrine Biosciences Inc. benefit from macro trends2025 Short Interest & Real-Time Volume Triggers - newser.com

Oct 05, 2025
pulisher
Oct 05, 2025

Will Neurocrine Biosciences Inc. (NB3) stock see valuation expansionEarnings Summary Report & Free Community Consensus Stock Picks - newser.com

Oct 05, 2025
pulisher
Oct 05, 2025

Why Neurocrine Biosciences Inc. (NB3) stock fits value portfolios2025 Market Sentiment & Free High Accuracy Swing Entry Alerts - newser.com

Oct 05, 2025
pulisher
Oct 05, 2025

What momentum shifts mean for Neurocrine Biosciences Inc.2025 Valuation Update & Fast Exit/Entry Strategy Plans - newser.com

Oct 05, 2025
pulisher
Oct 05, 2025

Is Neurocrine Biosciences Inc. (NB3) stock a buy during volatile marketsFed Meeting & Reliable Price Action Trade Plans - newser.com

Oct 05, 2025
pulisher
Oct 05, 2025

Why Neurocrine Biosciences Inc. stock is trending among retail traders2025 Market Outlook & Capital Efficient Trade Techniques - newser.com

Oct 05, 2025
pulisher
Oct 04, 2025

Neurocrine (NBIX) Gets a Buy from Bank of America Securities - The Globe and Mail

Oct 04, 2025
pulisher
Oct 03, 2025

Neurocrine Biosciences (NBIX): Exploring Valuation After Recent Share Price Movement - simplywall.st

Oct 03, 2025
pulisher
Oct 03, 2025

Can Neurocrine Biosciences Inc. stock maintain growth trajectoryPortfolio Update Report & Verified Momentum Stock Alerts - newser.com

Oct 03, 2025
pulisher
Oct 03, 2025

Will breakout in Neurocrine Biosciences Inc. lead to full recoveryRate Cut & Safe Entry Point Identification - newser.com

Oct 03, 2025
pulisher
Oct 03, 2025

Should I buy Neurocrine Biosciences Inc. (NB3) stock before earnings seasonWeekly Market Report & AI Enhanced Trade Execution Alerts - newser.com

Oct 03, 2025
pulisher
Oct 03, 2025

Why Neurocrine Biosciences Inc. stock could benefit from AI revolutionCEO Change & Long-Term Safe Investment Plans - newser.com

Oct 03, 2025
pulisher
Oct 01, 2025

Iambic Therapeutics Announces the Addition of Shalini Sharp to its Board of Directors - Business Wire

Oct 01, 2025

뉴로크린 바이오사이언시스 (NBIX) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

뉴로크린 바이오사이언시스 주식 (NBIX) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
GORMAN KEVIN CHARLES
Director
Aug 07 '25
Sale
126.41
106,322
13,440,281
514,596
$59.30
price up icon 2.76%
$10.09
price down icon 0.49%
drug_manufacturers_specialty_generic RDY
$14.03
price down icon 0.04%
$20.46
price up icon 0.02%
$445.86
price down icon 2.37%
자본화:     |  볼륨(24시간):